GSK, IQVIA launch Vaccine Track, a data trend platform to improve adult vaccination in US
Vaccine Track data insights revealed sustained decline of recommended adult immunisations, excluding flu vaccinations, across the US during the pandemic, especially in minority populations
GSK announced the launch of Vaccine Track, a platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus and enhance public health efforts, informed a company release.
The company statement informed, “Collective experience throughout the COVID-19 pandemic has elevated the public’s understanding of the value of vaccines and the importance of data in helping to prevent disease and death, especially in adult and older adult populations. Vaccination rates for CDC-recommended vaccines were low before the pandemic and despite heightened awareness, adult immunisation rates significantly declined during the pandemic, compounding already low rates. This is significant because even small drops in immunisations can lead to a resurgence of disease.”
The Vaccine Track platform will enable users to:
- Identify vaccination trends for adults 19+ in the US across multiple vaccines
- Scan immunisation claims data nationally and sub-nationally across years
- Track trends based on 2019 pre-COVID-19 baseline vaccination uptake
- Highlight where differences exist based on demographics (e.g., age, race/ethnicity, gender, payer type)
Vaccine Track data insights revealed sustained decline of recommended adult immunisations, excluding flu vaccinations, across the US during the pandemic. This was particularly true for minority populations, which already showed lower rates of immunisation pre-pandemic.
At the state level, as of December 2021 nearly half of the states in the US were facing greater than 30 per cent reductions in overall claims for recommended vaccines from 2019 pre-pandemic levels.